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Abstract
BACKGROUND 
Refractory gastrointestinal bleeding (GIB) secondary to gastrointestinal vascular 
malformations (GIVM) such as gastrointestinal angiodysplasia (GIAD) and gastric 
antral vascular ectasia (GAVE) remains challenging to treat when endoscopic 
therapy fails. Recently thalidomide has been suggested as a treatment option for 
refractory GIB.
AIM 
To determine the outcome of patients treated with thalidomide for refractory GIB 
due to GIVM.
METHODS 
IRB approved, single center, retrospective review of electronic medical records 
from January 2012 to November 2018. Patients age > 18 years old, who had > 3 
episodes of GIB refractory to medical or endoscopic therapy, and who had been 
treated with thalidomide for at least 3 mo were included. The primary endpoint 
was recurrence of GIB 6 mo after initiation of thalidomide.
RESULTS 
Fifteen patients were included in the study, all with significant cardiac, hepatic, or 
renal comorbidities. The cause of GIB was GIAD in 10 patients and GAVE in 5 
patients. Two patients were lost to follow up. Of the 13 patients followed, 38.5% (n 
= 5) had no recurrent GIB or transfusion requirement after treatment with 
thalidomide. Furthermore, 84.6% (n = 11) of patients had a reduction in 
transfusion requirements and hospitalizations for GIB. Thalidomide was 
discontinued in 2 patients due to cost (n = 1) and medication interaction (n = 1). 
Reported adverse reactions included fatigue (n = 3), neuropathy (n = 2), dizziness 
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(n = 1), and constipation (n = 1). Six patients died during follow up due to 
unknown cause (n = 4) and sepsis (n = 2).
CONCLUSION 
Thalidomide appears to be an effective treatment for refractory GIB due to GIAD 
or GAVE in a Western population with significant comorbidities.
Key words: Vascular malformation; Thalidomide; Refractory gastrointestinal bleeding; 
Gastric antral vascular ectasia; Angiodysplasia
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: Gastrointestinal vascular malformations (GIVM) consist of several types such as 
gastrointestinal angiodysplasias (GIAD) and gastric antral vascular ectasias (GAVE). 
Refractory gastrointestinal bleeding secondary to GIVM such as GIAD and GAVE 
remains challenging to treat when endoscopic therapy fails. Thalidomide appears to be an 
effective treatment for refractory gastrointestinal bleeding due to GIAD or GAVE in a 
Western population with significant comorbidities.
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INTRODUCTION
Gastrointestinal vascular malformations (GIVM) consist of several types such as 
gastrointestinal angiodysplasias (GIAD) and gastric antral vascular ectasias (GAVE). 
The pathogenesis of vascular malformations remains unclear, but is thought to be due 
to an imbalance of pro-angiogenic factors, such as vascular endothelial growth factor 
(VEGF), and anti-angiogenic properties leading to neovascularization[1]. In vitro studies 
have also demonstrated hypoxic conditions leading to increased expression of 
hypoxia-inducible-factor-1-α (HIF-1α) and HIF-2α, which upregulate VEGF and 
participate in the formation of GIVM[2]. Patients with GIVM can present with overt 
gastrointestinal bleeding (GIB) or iron deficiency anemia (IDA) due to chronic occult 
blood loss, and can be associated with significant morbidity and mortality.
GIAD are abnormal, dilated, tortuous vessels within the mucosal and submucosal 
layers and are the most common GIVM seen throughout the gastrointestinal tract. 
GIAD can account for up to 40% of occult GIB episodes[3]. Several chronic conditions 
have been associated with GIAD such as aortic stenosis, which can cause an acquired 
von Willbrand disease leading to increased GIB, also known as Heyde’s Syndrome. 
GIAD has also been shown to increase risk of GIB in patients with left ventricular 
assist devices (LVAD) as well as chronic renal failure.
GAVE is generally found in patients with chronic illnesses, such as liver disease, 
connective tissue diseases, and chronic renal failure. Bleeding from GAVE accounts for 
4% of upper GIB and is commonly found in women. Endoscopically, GAVE appears as 
either punctate lesions throughout the stomach or as red lesions radiating from the 
pylorus in stripes, known as “watermelon stomach”. Generally, it is found in the 
antrum with rare presentations in the proximal stomach. Histologically, GAVE is 
characterized by vascular ectasia of mucosal capillaries, focal thrombosis, spindle cell 
proliferation, and fibrinolysis.
Endoscopic therapy primarily with argon plasma coagulation (APC) is the mainstay 
of treatment for GIVM. However, GIVM refractory to endoscopic treatment is common 
and medications such as octreotide[7], tranexamic acid[8,9], hormonal therapy (estrogen-
progesterone)[10], and thalidomide[8,11-23] have all been studied in the management of 
recurrent GIB refractory to endoscopic therapy.
Thalidomide, known to have antiangiogenic properties by suppressing VEGF, has 
been shown in several studies (Table 1) to be a promising treatment option for 
refractory GIB from GIVM[11-22]. However, only one randomized control trial has been 
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Table 1 Studies evaluating the effect of thalidomide on treating gastrointestinal vascular malformations
Ref. No. patients Patient population Treatment
Follow-
up Results
Heidt et al[18], 
2006
1 von-Willebrand's disease type II-a 100 mg daily 11 mo Case report. Recurrent bleed within 2 wk of starting, at 11 months no further 
bleeding episodes. No side effects. Rebleeding upon cessation and with 
decreased dose
Dabak 
et al[15], 2007
3 Excluded: HIV positive on treatment. History of seizure disorder. Pregnant or lactating 
females. Patient with nonmalignant disease (congestive heart failure, uncontrolled 
infection, etc.). History of noncompliance
Thalidomide 100 mg 
daily and increased 
every 2 wk by 100 mg 
up to 400 mg daily
250 d Prospective study. 2/3 patients had responded to thalidomide with decrease 
transfusion requirements starting at 12 wk of study drug initiation. 1/3 
stopped due to lack of response. 1/3 had side effects and dose reduced to 50 
mg daily
Kamalaporn 
et al[19], 2009
7 Excluded: Severe medical conditions, such as heart or liver disease 50 mg daily, increased 
by 50 mg weekly up to 
200 mg daily for 6 mo
12 mo Case series. Response to treatment in 3/6 with no blood transfusions at 6 
months. 4/7 discontinued thalidomide because of side effects. Upon cessation 
of thalidomide, of the response group: 1 maintained response with no 
transfusion for 2 mo, then 1 unit every 4 wk. 1 required 2 u every 3-4 wk, 1 
passed from diabetes complications
Ge et al[10], 
2011
55 Excluded: Cirrhotic or portal gastropathy. Severe comorbidities of cardiac, pulmonary, 
renal, liver, hematological, rheumatologic, or uncontrollable diabetes mellitus or 
hypertension. History of severe bilateral peripheral neuropathy or seizure activity, 
thromboembolic disease, known thalidomide or iron allergy. Treatment with ASA, NSAID, 
antiplatelet, anticoagulant, or Chinese medications, gingko, echinacea, or 
immunomodulators. Pregnant or lactating. Undergoing cancer therapy via chemotherapy 
or radiation
Thalidomide 25 mg 
four times daily vs 
ferrous succinate 100 
mg four times daily. 
Both for 4 mo
39 mo (8-
52)
Prospective, randomized, parallel control trial. Effective response rate of 
decrease bleed > 50% first year of follow-up period in thalidomide 71.4% vs 
iron supplementation response 3.7% (P < 0.001). Secondary endpoints of rates 
of bleeding cessation, blood transfusion, overall hospitalization, and 
hospitalization for bleeding demonstrated thalidomide was more effective. 
Level of VEGF significantly reduced in thalidomide group (P < 0.001). Minor 
side effects reported in thalidomide group
Garrido 
Serrano 
et al[17], 2012
19 Cirrhosis Thalidomide 200 mg 
daily for 4 mo
4 mo Prospective study. Mean hemoglobin before thalidomide 7 g/dL, after 2 mo 9 
g/dL and at end of 4 mo 10 g/dL. Side effects included HE (2/19), sensitive 
axonal polyneuropathy (1/19) which resolved after withdrawal of 
thalidomide
Ray et al[20], 
2014
1 LVAD 50 mg twice daily 12 mo Case report. No further bleeding after starting thalidomide and remained on 
warfarin. No reported side effects
Bond et al[12], 
2015
1 Cutaneous T-cell lymphoma 100 mg daily 6 mo Case report. No further bleeding episodes at 6 mo. Side effects of dizziness 
and unsteadiness
Draper 
et al[23], 2015
8 LVAD 50 mg twice daily 
increased by 50 mg 
weekly up to 200 mg 
daily
Not 
included
Case series. No recurrence of bleeding 5/8, reduced bleeding 2/8. Death 1/8 
within 1 wk of starting due to sepsis. Side effects in 2/8
Chen et al[14], 
2016
80 Excluded: Cirrhotic or portal hypertension gastropathy. Severe cardiac, pulmonary, renal, 
liver, pancreas, hematological, or rheumatologic comorbidities, uncontrolled diabetes 
mellitus or hypertension, or renal insufficiency without hemodialysis or peritoneal dialysis. 
Severe bilateral peripheral neuropathy or seizure, thromboembolic disease. Known 
thalidomide allergy, treatment with any systemic or oral topical corticosteroids, NSAID, 
any putative immunomodulators, or antiangiogenic agents. Pregnant or lactating. Alcohol 
and/or drug abuse. Poor compliance
Thalidomide 25 mg 
four times a day for 4 
mo
42.6 mo 
(12-120)
Retrospective study. In first year of follow-up, overall response rate was 77.5% 
(62/80) with 41.3% (33/80) achieving complete cessation. Overall response 
rate of 79.5% (62/78). Adverse effects in 60% with serious effects in 31.3% 
(25/80)
Chan et al[13], 11.4 mo Case series. No further bleeding. When medications stopped, recurrence of 4 LVAD 50 mg daily
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2017 (7-24) bleeding, with restart of medication and cessation of bleeding
Duarte 
et al[16], 2017
1 Glanzmann's thrombasthenia 50 mg daily, after 15 d 
increased to 100 mg 
daily
6 mo Case report. Recurrent bleeding at 5 mo, requiring transfusions. Thalidomide 
suspended at 5 mo. Death due to sepsis and hemorrhage
Seng et al[21], 
2017
11 LVAD Thalidomide 50 mg 
daily
186 d (3-
512 d)
Retrospective study. Resolution of bleeding in 90.9% (10/11). Discontinued in 
6 (63.6%) due to resolution of bleeding (n = 4) or side effects (n = 2), with GIB 
recurring in 4 of these patients. Adverse effects in 5/11 patients including 
pump thrombosis (n = 2) leading to death. 4/11 died during the study with 1 
from continued bleeding and 1 from septic shock
NSAID: Non-steroidal anti-inflammatory; ASA: Aspirin; HE: Hepatic encephalopathy; LVAD: Left ventricular assist device; GIB: Gastrointestinal bleeding.
reported by Ge et al[8] in a Chinese population in 2011. In addition, this study has an 
extensive exclusion criteria, such as comorbidities of cardiac, pulmonary, liver, renal, 
hematologic, and rheumatologic disorders; history of thromboembolic disease; or 
patient on antiplatelet agent or anticoagulation. Given that patients with recurrent GIB 
from GIVM are frequently elderly with several comorbidities, it is unclear whether the 
results of this study can be extrapolated to other patient populations. Whereas there 
are several reported case series on the effects of thalidomide on patient with cirrhosis 
or LVAD[13,20-22], many other studies excluded patients with significant comorbidities 
(Table 1). We therefore decided to conduct a retrospective study of thalidomide in 
treating refractory GIB from GIVM in a Western population with significant 
comorbidities at a tertiary medical center.
MATERIALS AND METHODS
Study population
This is a retrospective study of patients diagnosed with GIVM at the Division of 
Gastroenterology, Washington University Medical Center/Barnes-Jewish Hospital, 
from January 2012 to November 2018 who were treated with thalidomide. The 
institutional review board at Washington University in St. Louis, Missouri approved 
the study.
Inclusion criteria
Aged ≥ 18 years old; male and post-menopausal females; > 3 episodes of GIB with > 1 
episode of refractory bleeding; documented vascular malformation (either GIAD or 
GAVE) on either upper endoscopy (esophagogastroduodenoscopy) or colonoscopy 
and if bleeding was not initially found, subsequent balloon enteroscopy or capsule 
endoscopy; and treated with thalidomide for at least 3 months. Refractory bleeding 
was defined as recurrent bleeding requiring > 2 transfusions after failing 2 treatments 
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with endoscopic therapy using APC or medical therapies, such as octreotide, estrogen, 
or aminocaproic acid. Exclusion criteria: Patients with other causes of GIB, patients 
with allergy to thalidomide, women who were pregnant or lactating, and pre-
menopausal women.
Thalidomide treatment
All of the patients included in this study were prescribed thalidomide (Thalomid®) by 
a single certified provider (Chen CH) according to the Thalomid Risk Evaluation and 
Mitigation Strategy (REMS) program of Celgene (NJ, United States). Patients were 
started on thalidomide for more than 3 episodes of GIB requiring blood transfusion 
with recurrent GIB after failing at least two treatments with endoscopic therapy or 
medical therapy. Patients were started on thalidomide 50 mg twice daily or 100 mg 
once daily. This initial dose was increased or decreased depending on patient’s 
response and ability to tolerate the medication. During the treatment period, patients 
were monitored by phone every 4 wk and in the outpatient clinic every 3 to 6 mo. 
Complete blood count and comprehensive metabolic panel were monitored every 3 to 
6 mo.
In the event of an adverse side effect, thalidomide was temporarily or permanently 
discontinued depending on the severity of the side effect and the patient’s tolerability. 
During treatment with thalidomide, adjunct therapy such as blood transfusions or 
repeat endoscopic treatment were performed as necessary at the discretion of treating 
physicians. Transfusion was given to patients when hemoglobin level fell below 7.0 
g/dL. Patients were continued on antiplatelet or anticoagulation or iron 
supplementation if they were taking it prior to initiation of thalidomide.
Data collection
Data collected from electronic medical records included patient’s demographics, 
medical history, comorbidities, medications, number of hospitalizations, endoscopic 
treatment, and number of blood transfusions.
Assessment
The primary endpoint was to assess the recurrence of GIB 6 mo after the initiation of 
thalidomide. The secondary endpoints were the number of hospitalizations, blood 
transfusion requirements, and endoscopic treatments. A bleeding recurrence was 
defined as a GIB episode with hemoglobin level less than 7.0 g/dL resulting in a blood 
transfusion. All bleeding episodes of the patients studied were due to GIVM. Patients 
were encouraged to keep in close contact with patient care coordinators to update the 
team on their progress, possible side effects from thalidomide, and any bleeding 
episodes requiring blood transfusions or hospitalizations that occurred in between 
office visits.
RESULTS
A total of 15 patients were included in this study. Table 2 details the demographic and 
clinical characteristics of patients included in this study. Mean age was 69 (range: 58-
83) years old. There were 6 women (40%) and 9 men (60%). Eleven patients were 
Caucasian (73.3%) and four patients were African American (26.7%). Body mass index 
median was 28.6 (range: 21-48). All patients in this study had multiple comorbidities. 
Six patients had cirrhosis (n = 5) or non-cirrhotic portal hypertension; Child-Pugh class 
A (n = 2), class B (n = 3). Three had end stage renal disease (ESRD) on hemodialysis, 3 
had chronic kidney disease, stage 3 (n = 2), stage 5 (n = 1). Three had a LVAD, 10 had 
hypertension, 5 had diabetes, 1 had myelodysplastic syndrome (MDS) and non-
Hodgkin’s lymphoma, 1 had polyclonal gammopathy, 2 had aortic stenosis, and 1 had 
hereditary hemorrhagic telangiectasias.
The cause of GIB was GIAD in 10 patients (66.6%) and GAVE in 5 patients (33.3%). 
Prior to treatment with thalidomide, 6 patients were previously treated with 
octreotide, 1 treated with estrogen, and 1 treated with aminocaproic acid. All patients 
received at least two treatments of APC before starting thalidomide, except for one 
whose source of bleeding was not reachable via endoscopy. All patients prior to the 
initiation of thalidomide had anemia with average hemoglobin level of 7.9 g/dL. Five 
patients were on iron supplement when referred to our care and 3 patients with iron 
deficiency were not on iron supplement. Eight patients continued with iron 
supplementation after initiation of thalidomide treatment. Five patients remained on 
antiplatelet or anticoagulation such as aspirin, warfarin, clopidogrel, or cilostazol. Two 
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Table 2 Patient characteristics
Patient Age Sex Comorbidities Cause of GIB
Prior failed 
treatments Iron supplementation Comments
1 58 M LVAD GIAD Octreotide
2 67 F ESRD GIAD Sodium ferric gluconate Aspirin
3 70 M LVAD GIAD Octreotide Ferrous sulfate Warfarin
4 61 F Cirrhosis GIAD Ferrous sulfate
5 81 M LVAD GIAD Octreotide Ferrous sulfate Aspirin, warfarin
6 83 M CAD, AS, AAA, CVA GIAD Octreotide, estrogen Polysaccharide iron Aspirin, cilostazol, 
plavix
7 72 M Hepatoportal sclerosis GAVE
8 69 F Polyclonal 
gammopathy
GIAD
9 70 F ESRD, HHT GIAD Octreotide Ferrous sulfate
10 62 M Cirrhosis GAVE Ferrous fumarate
11 58 M Cirrhosis, CHF, ESRD GAVE Octreotide Ferrous sulfate
12 64 F Cirrhosis, MDS, NHL GAVE
13 80 F AS GIAD
14 74 M NSCLC, AFIB, MDS GIAD Lost to follow-up
15 68 M AFIB, CHF, Cirrhosis GAVE Aspirin, warfarin, 
lost to follow-up
LVAD: Left ventricular assist device; ESRD: End stage renal disease; CAD: Coronary artery disease; AS: Aortic stenosis; AAA: Abdominal aortic aneurysm; 
CVA: Cerebrovascular accident; HHT: Hereditary hemorrhagic telangiectasia; CHF: Congestive heart failure; MDS: Myelodysplastic syndrome; NHL: Non-
Hodgkin lymphoma; NSCLC: Non-small cell lung cancer; AFIB: Atrial fibrillation; GIAD: Gastrointestinal angiodysplasia; GAVE: Gastric antral vascular 
ectasia.
patients discontinued thalidomide: One due to cost and another due to drug 
interaction with methadone, after being treated with thalidomide for 17 mo and 3 mo 
respectively. Two other patients were lost to follow up.
During the one year prior to starting thalidomide, of the 13 patients who remained 
in the study, the mean number of hospital admissions for GIB was 5.46 (range, 1-20 
admissions), the mean number of packed red blood cell (PRBC) transfusions was 31 
units (range, 8-99 units) and the mean number of endoscopic treatments was 4.54 
(range, 0-12 endoscopic treatments).
Thalidomide was started at either 50 mg twice daily or 100 mg once daily. 
Ultimately the dose of thalidomide ranged from 50 mg to 200 mg daily, titrating to 
patients’ response and tolerability. The average duration of treatment on thalidomide 
was 28 mo (range, 3-45 mo).
Of the 13 patients followed (range 3-45 mo), 9 patients had GIAD and 4 patients had 
GAVE. GIAD were located in the gastric fundus (n = 1), duodenum (n = 3), jejunum (n 
= 5), ileum (n = 1), and hepatic flexure of colon (n = 1). After initiation of thalidomide 
treatment for 6 mo, 5 patients (38.5%) met our primary endpoint with no recurrent GIB 
episodes during follow-up (Figure 1). Of these 5 patients, 2 had an LVAD and GIAD, 2 
had cirrhosis and GAVE, and 1 had cirrhosis and GIAD. Another 6 patients (46.2%) 
had both marked reduction in transfusion requirements and hospitalizations for GIB 
(Figure 1 and Table 3). Two patients had increased transfusion after treatment with 
thalidomide for 3 and 30 mo. The requirement of endoscopic treatments decreased in 
11 patients (84.6%) after the initiation of treatment. Of the 11 patients who responded 
favorably to treatment, the effect of thalidomide could be observed after 3 mo of 
treatment. Significant reduction of GIVM could be seen during follow-up endoscopies, 
as demonstrated in a patient with GAVE who underwent esophagogastroduo-
denoscopy 3 and 8 mo after treatment with thalidomide (Figure 2).
All 4 patients who remained on anticoagulation or antiplatelet therapy, including 2 
with an LVAD, had a significant decrease in GIB as demonstrated by a decreased 
transfusion requirements and hospitalizations. Additionally, all 4 patients with 
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Table 3 The effect of thalidomide treatment on refractory gastrointestinal bleeding due to vascular malformation
Number of hospitalizations 
due to GIB Units RBC transfused
Number of endoscopic 
treatments (APC)
Patient
Duration 
of 
treatment 
(mo)
Recurrence 
of bleeding 
after 6 mo 1 yr before 
thalidomide
After 
starting 
thalidomide
1 yr before 
thalidomide
After 
starting 
thalidomide
1 yr before 
thalidomide
After 
starting 
thalidomide
Comments
1 6 No 2 0 21 0 2 0
2 19 Yes 4 1 8 12 3 1 Side effect of 
fatigue and 
dizziness
3 45 No 2 0 20 0 1 0 Side effect of 
neuropathy
4 14 No 1 0 Weekly 
transfusion
0 6 0 Side effect of 
fatigue and 
constipation. 
Death
5 44 Yes 5 1 14 4 4 1 Side effect of 
neuropathy. 
Death, Sepsis
6 17 Yes 6 5 Biweekly 
transfusion
4 3 2 Stopped due to 
cost. Death
7 24 Yes 9 3 33 9 4 10 Death
8 30 Yes 1 2 2 8 2 1 Side effect of 
fatigue
9 28 Yes 17 8 48 32 12 1 Death
10 3 NA 1 0 3 0 1 0 Stopped due to 
drug 
interaction
11 25 No 20 1 65 3 12 1 Death, Sepsis
12 6 No 2 0 99 0 9 4 Side effect of 
neutropenia
13 3 NA 1 1 12 16 1 1
GIB: Gastrointestinal bleeding; APC: Argon plasma coagulation; RBC: Red blood cell; NA: Not available.
cirrhosis had a marked decrease in hospitalizations, blood transfusions, and 
endoscopic treatments. The 3 patients with ESRD on dialysis and 3 patients with 
chronic kidney disease all showed improvement in transfusion requirements after 
treatment.
Reported adverse reactions were documented in 6 of the 13 patients (46%), 
including fatigue (n = 3), neuropathy (n = 2), constipation (n = 1), and dizziness (n = 1). 
Worsening neutropenia was observed in a patient with concurrent MDS, with 
stabilization of white blood cell counts after a dose reduction of thalidomide from 100 
mg to 50 mg daily. GIB did not recur after this dose reduction. Six patients died during 
the follow-up period of this study. Five patients died while on thalidomide due to 
causes unrelated to recurrent GIB and one patient died from unknown causes after 
discontinuing thalidomide due to cost. All patients who died while taking thalidomide 
had been treated for over 1 year. Of the 5 patients who died while taking thalidomide, 
2 died from complications due to sepsis, 1 sustained a traumatic fall and passed away 
in hospice, and 2 died from unknown causes.
DISCUSSION
This retrospective study aimed to examine the effect of thalidomide on refractory GIB 
due to GIVM. Our results demonstrated that thalidomide appears to be an effective 
medical therapy for this very challenging patient population. Five out of 13 patients 
(38.5%) followed in our study had no recurrent GIB after treatment with thalidomide, 
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Figure 1  Units of packed red blood cell transfused before and after initiation of thalidomide.
Figure 2  Endoscopic pictures of gastric antral vascular ectasia before and after treatment with thalidomide. A: Gastric antral vascular ectasia 
(GAVE) with visible bleeding prior to initiation of thalidomide; B: GAVE 3 mo after initiation of thalidomide; C: GAVE 8 mo after initiation of thalidomide.
while overall 11 out of 13 patients (86.4%) had decrease in recurrence of GIB, 
hospitalizations, blood transfusions and endoscopic therapies.
Previous studies and case reports have reported similar results with thalidomide in 
treating recurrent GIB from GIVM[8,10-22]. Whereas the only randomized controlled trial 
so far by Ge et al[10] from China found a response rate of 71.4%, patients with cardiac, 
pulmonary, hepatic, renal, and other comorbidities were excluded from the study. In a 
follow-up retrospective study by the same group with 80 patients, the response rate to 
thalidomide in patients with or without comorbidities was 76.7% and 78% 
respectively, although this study again excluded patients with severe comorbidities 
such as cirrhosis and severe cardiac and renal conditions[14]. Therefore, it is unclear 
whether these results could be applied to other patient populations with significant 
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comorbidities. Three previous case series of patients with an LVAD[13] and one case 
study of patients with liver cirrhosis[17] found thalidomide effective in treating 
refractory GIB patients with these comorbidities. The response rate in our study was 
84.6%, comparable to other previous studies. The patients in our study represent the 
most challenging recurrent GIB patients we encounter in a tertiary referral medical 
center, as evidenced by their multiple comorbidities, and the average number of 
admissions (5.46) and transfusions (31 units of PRBC) one year before the initiation of 
thalidomide. Our study demonstrated that thalidomide remains an effective treatment 
for refractory GIB from GIVM in a Western population, including patients with severe 
comorbidities such as LVAD, cirrhosis, and ESRD on dialysis.
Anticoagulation or antiplatelet agents are frequently discontinued in the setting of 
GIB. However, this increases the risk of thromboembolism especially in patients with 
significant cardiovascular comorbidities and patients with LVAD. Four of our patients 
continued their anticoagulation or antiplatelet agents such as warfarin, aspirin, 
clopidogrel, or cilostazol, and still responded favorably to thalidomide. Our results 
suggest that it may not be necessary to discontinue anticoagulation or antiplatelet 
agents in this group of patients with severe multiple comorbidities while on 
thalidomide. One patient with severe GAVE and platelet count < 30000/mL due to 
MDS received 99 units of PRBC in the one year before thalidomide treatment, and 
required no transfusion after treatment. More data is needed to determine whether 
correcting thrombocytopenia is necessary when treating GIVM with thalidomide.
Thalidomide is thought to inhibit angiogenesis by suppressing VEGF. In our study, 
the effects of thalidomide became apparent after about 3 mo of treatment, consistent 
with the observation of previous studies[15,17,19]. The interval between the initiation of 
thalidomide and the decrease of GIB likely reflects the time it takes to change the 
balance between anti- and pro- angiogenesis factors in the existing GIVM and 
suppressing new GIVM formation. The effectiveness of thalidomide in treating GIB 
from GIVM as shown in this and other studies suggests that we could potentially 
explore other angiogenesis inhibitors to treat GIVM.
The dose of thalidomide in previous studies ranged from 50 mg to 400 mg per day. 
Dosing and efficacy could possibly be related to a patient’s body mass index (BMI), as 
was suggested by Seng et al[20] where BMI median was 18. The initial dose of 
thalidomide in their study was 50 mg daily for all patients, whereas other studies 
typically used at least 100 mg daily[16,20]. In our study, the dose of thalidomide was 
started at 100 mg daily, with the final dosage ranged from 50 to 200 mg daily. The 
median BMI of our patients was 28. Seven of our patients improved on thalidomide 
100 mg daily, whereas two patients did not see improvement of bleeding until the 
dose of thalidomide was increased to 150 and 200 mg daily, with a BMI of 28 and 48 
respectively. Two non-responders in our study were treated with 200 mg daily with a 
BMI of 30, and 100 mg daily with BMI of 24. We do not see a clear association of dose, 
BMI, and effectiveness based on our data. Further study is needed to elucidate the 
relationship between the response to thalidomide and BMI.
The common side effects of thalidomide include drowsiness, fatigue, dizziness, 
neuropathy, skin rash, and constipation. The most common side effect reported in our 
study was fatigue (n = 3). Fatigue and dizziness were reported in one patient who 
mistakenly took double dose of thalidomide, and resolved once she went back to the 
prescribed dose. Neutropenia (n = 1) occurred in a patient with MDS, and resolved 
upon reducing the dose of thalidomide to 50 mg daily and without recurrence of GIB. 
Neuropathy was described in 2 patients, one of which had a history of parkinsonism 
and another with a history of diabetes. No thromboembolism was observed in our 
study, although the reported risk of thromboembolism associated with thalidomide is 
mainly seen in patients with multiple myeloma on chemotherapy. Five patients died 
while on thalidomide and one patient died after discontinuation of thalidomide due to 
cost. The cause of death does not appear to be associated with thalidomide (sepsis 2, 
fall 1) in 3 patients. The cause of death in 2 patients was unknown and therefore 
unclear if it is related to thalidomide.
The major limitations of this study are the limitations inherent with a retrospective 
study, such that we were not able to control for variables like the degree of IDA or 
whether patients were taking iron supplement. Another limitation is our small sample 
size (n = 15). Most of our patients with refractory GIB were elderly with limited 
income. Many patients could not receive treatment with thalidomide due to cost or 
lack of insurance coverage. Even more patients declined treatment with thalidomide 
due to concern of potential side effects in the context of their multiple comorbidities 
after reading the patient medical information from REMS. Nevertheless, our sample 
size is the second largest from the Western World in the literature. In addition, our 
primary and secondary outcomes were objective measures and less susceptible to 
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reporting bias. With more data published on thalidomide in recurrent GIB, we may see 
improvement in its coverage or patients’ acceptance.
In conclusion, the treatment of patients with refractory GIB due to GIVM remains a 
daunting task with limited options. Our study suggests that thalidomide appears to be 
an effective treatment for refractory GIB due to GIAD or GAVE in a Western 
population with significant comorbidities such as LVAD, portal hypertension, and 
ESRD.
ARTICLE HIGHLIGHTS
Research background
Gastrointestinal vascular malformations (GIVM) consist of several types such as 
gastrointestinal angiodysplasias (GIAD) and gastric antral vascular ectasias (GAVE). 
GIAD are abnormal, dilated, tortuous vessels within the mucosal and submucosal 
layers and are the most common GIVM seen throughout the gastrointestinal tract. 
GAVE is generally found in patients with chronic illnesses, such as liver disease, 
connective tissue diseases, and chronic renal failure. Refractory gastrointestinal 
bleeding (GIB) secondary to GIVM remains challenging to treat when endoscopic 
therapy fails. Endoscopic therapy with argon plasma coagulation (APC) is the 
mainstay of treatment for GIVM. However, GIVM refractory to endoscopic treatment 
is common and medications such as octreotide, tranexamic acid, hormonal therapy 
such as estrogen-progesterone, and thalidomide have all been studied in the 
management of recurrent GIB refractory to endoscopic therapy. Thalidomide, known 
to have antiangiogenic properties by suppressing VEGF, has been suggested recently 
as a treatment option for refractory GIB.
Research motivation
Only one randomized control trial demonstrating the efficacy of thalidomide for 
treating refractory GIB due to GIVM has been published in 2011 in a Chinese 
population. However, the study had extensive exclusion criteria and it is unclear 
whether the results of the study can be extrapolated to other patient populations. We 
therefore decided to conduct a retrospective study of thalidomide in treating 
refractory GIB from GIVM in a Western population with significant comorbidities at a 
tertiary medical center.
Research objectives
To evaluate thalidomide as a treatment option for patients who suffer from refractory 
GIB due to GIVM.
Research methods
Single center, IRB approved, retrospective review of electronic medical records from 
January 2012 to November 2018. Patients age > 18 years old, who had > 3 episodes of 
GIB refractory to medical or endoscopic therapy and documented to be due to GIVM, 
and who had been treated with thalidomide for at least 3 months were included. 
Refractory bleeding was defined as recurrent bleeding requiring > 2 transfusions after 
failing 2 treatments with endoscopic therapy using APC or medical therapies, such as 
octreotide, estrogen, or aminocaproic acid. The primary endpoint was recurrence of 
GIB 6 mo after initiation of thalidomide. The secondary endpoints were the number of 
hospitalizations, blood transfusion requirements, and endoscopic treatments.
Research results
Fifteen patients were included in the study, all with significant cardiac, hepatic, or 
renal comorbidities. The cause of GIB was GIAD in 10 patients and GAVE in 5 
patients. Two patients were lost to follow up. Of the 13 patients followed, 38.5% (n = 5) 
had no recurrent GIB or transfusion requirement after treatment with thalidomide. 
Furthermore, 84.6% (n = 11) of patients had a reduction in transfusion requirements 
and hospitalizations for GIB. Thalidomide was discontinued in 2 patients due to cost (
n = 1) and medication interaction (n = 1). Reported adverse reactions included fatigue (
n = 3), neuropathy (n = 2), dizziness (n = 1), and constipation (n = 1). Six patients died 
during follow up due to unknown cause (n = 4) and sepsis (n = 2).
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Research conclusions
Our results demonstrated that thalidomide appears to be an effective medical therapy 
for refractory GIB due to GIVM. The response rate in this study was 84.6%, 
comparable to other previous studies. The patients in our study represent the most 
challenging recurrent GIB patients in a tertiary referral medical center, as evidenced by 
their multiple comorbidities, and the average number of admissions (5.5) and 
transfusions (31 units of PRBC) one year before the initiation of thalidomide. Our 
study demonstrated that thalidomide remains an effective treatment for refractory GIB 
from GIVM in a Western population, including patients with severe comorbidities 
such as left ventricular assist device, cirrhosis, and end-stage renal disease on dialysis.
Research perspectives
Based on the results of this study, future research should include prospective 
randomized control trial with a larger patient population so that we can examine the 
effect of thalidomide on each comorbidity with sufficient power.
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